TFEB regulation:new insight into treatment of kidney diseases
10.3969/j.issn.1000-4718.2018.04.028
- VernacularTitle:TFEB调控——肾脏疾病治疗的新思路
- Author:
Ting-Ting LI
1
;
Shu-Jun WANG
;
Chen YANG
;
Hong-Luan WU
;
Zhi-Hang LI
;
Hua-Feng LIU
;
Wei-Jing LIU
Author Information
1. 湛江市慢性肾脏病防控重点实验室
- Keywords:
Transcription factor EB;
Renal cell carcinoma;
Diabetic kidney disease;
Cystine nephropathy
- From:
Chinese Journal of Pathophysiology
2018;34(4):754-759
- CountryChina
- Language:Chinese
-
Abstract:
Transcription factor EB(TFEB)is a member of the MiTF/TFE family and plays an important role in cell stress,metabolism,cancer and so on.There are relatively few studies on the role of TFEB in renal diseases.TFEB was initially found to be highly expressed in TFEB-fusion renal cell carcinoma and plays a key role in the development of re-nal cell carcinoma.Blocking the downstream signaling pathway activated by TFEB would be a promising treatment for TFEB-fusion renal cell carcinoma.On the contrary,the expression of TFEB in renal intrinsic cells is decreased in diabetic kidney disease,leading to a blockage in the autophagy-lysosome pathway.TFEB enhances the ability of cell stress and self-repair,and then delays the progress of diabetic kidney disease.In cystine nephropathy,TFEB expression is reduced in re-nal tubular epithelial cells and compensatory activation is insufficient as well.TFEB over-expression effectively eliminates intracellular cystine and repairs damaged lysosome,which is expected to alleviate or cure the Fanconi syndrome.In summa-ry,TFEB plays a key role in different kidney diseases,and targeted regulation of TFEB provides new hope for the treatment of kidney diseases.
